References
- Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Curr Med Res Opin 2017;33:797-801
- Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf [Last accessed 25 April 2017]
- Itou M, Kawaguchi T, Taniguchi E, et al. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013;19:2298-306
- Elgharably A, Gomaa AI, Crossey MM, et al. Hepatitis C in Egypt – past, present, and future. Int J Gen Med 2016;10:1-6
- El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat 2017;24:262-7
- Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer 2009;124:690-7
- Lim CT, Kumar R. Hepatitis B and concomitant hepatic steatosis. Ann Transl Med 2017;5:38
- Shi YX, Huang CJ, Yang ZG. Impact of hepatitis B virus infection on hepatic metabolic signaling pathway. World J Gastroenterol 2016;22:8161-7
- Chang ML. Metabolic alterations and hepatitis C: from bench to bedside. World J Gastroenterol 2016;22:1461-76
- Ballestri S, Nascimbeni F, Romagnoli D, et al. Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis C virus infection – liver: the “musketeer” in the spotlight. Int J Mol Sci 2016;17:355
- Haga Y, Kanda T, Sasaki R, et al. Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis. World J Gastroenterol 2015;21:12989-95
- García-Compeán D, González-González JA, Lavalle-González FJ, et al. Current concepts in diabetes mellitus and chronic liver disease: clinical outcomes, hepatitis C virus association, and therapy. Dig Dis Sci 2016;61:371-80
- Huang YW, Wang TC, Lin SC, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis 2013;57:1695-702
- Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009;29(Suppl2):3-12
- Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 2016;65:1109-23
- Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol 2015;21:6820-34
- Katsiki N, Athyros VG, Karagiannis A, et al. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol 2014;29:389-95
- Bril F, Cusi K. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2016;45:765-81
- Katsiki N, Athyros VG, Mikhailidis DP. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. J Diabetes Complications 2017;31:521-2
- Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. an expert panel statement. Metabolism 2017;71:17-32
- Hussain M, Majeed Babar MZ, Hussain MS, et al. Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease. Pak J Med Sci 2016;32:1396-401
- Macauley M, Hollingsworth KG, Smith FE, et al. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab 2015;100:1578-85
- Katsiki N, Doumas M, Athyros VG, et al. Hyperuricemia as a risk factor for cardiovascular disease. Expert Rev Cardiovasc Ther 2015;13:19-20
- Katsiki N, Papanas N, Fonseca VA, et al. Uric acid and diabetes: is there a link? Curr Pharm Des 2013;19:4930-7
- Katsiki N, Karagiannis A, Athyros VG, et al. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013;14:397-402
- Katsiki N, Athyros VG, Karagiannis A, et al. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011;9:698-705
- Shimodaira M, Niwa T, Nakajima K, et al. Beneficial effects of vildagliptin on metabolic parameters in patients with type 2 diabetes. Endocr Metab Immune Disord Drug Targets 2015;15:223-8